The significance of the study lies in its attempt to bridge two levels of description. Molecular dynamics (MD) simulations are the workhorse of structural biology: they track every atom of a peptide and its surrounding water molecules over time, producing rich but computationally expensive movies of molecular motion. The MMFs method, by contrast, works from first principles at the level of individual non-covalent interactions. It calculates how electrostatic attractions, repulsions, hydrogen bonds, and hydrophobic contacts between neighboring side chains generate torques that twist the peptide backbone, ultimately determining the dihedral angles that define the molecule’s fold. What the new study adds is a way to fold the physics of pH into that mechanical picture.

To test the idea, the researchers selected a well-characterized model system: a beta-hairpin peptide catalogued in the Protein Data Bank under the code 1K43, originally described by Pastor and colleagues in 2002. A beta-hairpin is one of the simplest folded structures a peptide can adopt, two short strands connected by a turn, and this particular sequence contains an abundance of pH-responsive residues, including arginine, lysine, glutamate and tyrosine. That makes it an ideal proving ground for asking whether a calculation-based method can track how protonation and deprotonation events remodel the network of interactions that holds the hairpin together.

The researchers began by validating their tool against known reality. Starting from a fully unfolded model of the peptide, in which every backbone dihedral angle was set to 180 degrees, they applied the MMFs methodology to rebuild the folded structure purely from the mechanical consequences of side-chain interactions. The resulting model agreed with the experimental NMR structure with a root-mean-square deviation (RMSD) of 2.400 angstroms, a level of agreement the authors attribute mainly to the known difficulty of modeling the flexible terminal residues, arginine 1 and arginine 14. With the reference structure established, the team could then use it as a baseline for comparing pH-altered versions of the peptide.

The key methodological extension involves the pKa values of the ionizable side chains. At low pH, acidic groups such as the carboxylate of glutamate become protonated and lose their charge; at high pH, basic groups such as the amine of lysine and the phenolic groups of tyrosine shed their protons. Each of these events eliminates or creates specific non-covalent interactions, and the MMFs framework now subtracts the corresponding partial contributions to the backbone dihedral angles. At acidic pH, for example, the protonation of the terminal carboxylate of arginine 14 and the side-chain carboxyl of glutamate 12 required the removal of electrostatic attraction, repulsion and hydrogen-bond terms from the affected residues. At pH 11, deprotonation of the two tyrosines forced the team to account for a newly created electrostatic attraction between the negatively charged tyrosine 11 side chain and arginine 14, while removing the hydrogen bonds that the neutral phenols previously donated.

One of the more surprising findings concerns glycine, the smallest amino acid. The calculations revealed that glycine residues require a fundamentally different treatment under acidic conditions than under neutral or basic ones. At low pH, the phi dihedral angle of a glycine is influenced by all possible non-covalent interactions with its neighbors, apparently because the achiral nature of glycine’s central carbon permits extra local flexibility under acidic conditions. At higher pH, a simpler rule based on coplanarity with the preceding residue sufficed. To complete the framework, the authors also derived new equations for the psi dihedral angle covering combinations of secondary-structure contexts, such as left-handed alpha-helices paired with beta-strands or pi-helices, that had not appeared in their previous formulations.

To check whether these hand-calculated structures were trustworthy, the team ran 250-nanosecond molecular dynamics simulations of the peptide at pH 3, pH 7.4 and pH 11 using the YASARA engine, with careful control of protonation states, physiological salt concentration, and periodic boundary conditions. Protonation assignments were cross-validated with four independent pKa prediction tools: YASARA’s built-in method, H++, PypKa and KaML, which produced highly consistent values, for instance predicting a pKa of roughly 4.2 to 4.3 for glutamate 12 and about 10.3 to 10.8 for lysine 3. The simulations sampled conformations every 200 picoseconds, and the researchers compared the MMFs-predicted structures against conformers extracted at 25-nanosecond intervals throughout each trajectory.

The verdict was a consistent story across all three pH conditions. At pH 3, the peptide remains essentially stable: the MMFs-derived structure differed from the experimental reference by only 2.486 angstroms and matched the MD ensemble with an RMSD as low as 2.69 angstroms. At physiological pH 7.4, the hairpin partially holds together but grows more flexible, with the corresponding RMSD values rising to 3.922 angstroms against the experimental structure and a best match of 3.31 angstroms against the MD trajectory. At pH 11, the structure largely falls apart, showing an RMSD of 6.761 angstroms versus the experiment, a signature of substantial loss of native organization. Strikingly, the MMFs prediction at high pH matched the MD ensemble with an RMSD of just 2.88 angstroms, the best agreement of all, confirming that the method correctly captures the consequences of deprotonating lysine and the two tyrosines.

That agreement matters because of what it could enable. Designing peptides for drug discovery requires knowing that a candidate sequence will hold a defined shape long enough to bind its biological target, rather than flopping into an unproductive conformation. pH-responsive peptides are also the basis of so-called conformational switches, molecules that deliberately change shape in response to acidity, with applications ranging from biosensors to metal-ion chelators to drug delivery systems that release their cargo in the acidic environment of tumors or endosomes. A fast, interaction-based calculation that maps out the pH range in which a given sequence stays folded, or falls apart, could dramatically shorten the design cycle for such systems, without waiting for full-scale simulations to finish.

The authors caution, as they have in earlier work, that terminal residues remain the weak point of the MMFs approach, and the glycine behavior under acidic conditions adds a layer of system-specific complexity. But the overall message is that a mechanical, bond-by-bond accounting of protonation effects can reproduce the same pH-dependent trends that expensive atomistic simulations reveal. The researchers suggest their refined framework could inform future simulation platforms dedicated to peptide folding mechanisms, offering a complementary lens on how the invisible chemistry of a single proton reshapes the architecture of an entire molecule, one non-covalent interaction at a time.

Subject of Research: pH-dependent conformational transitions in a beta-hairpin peptide predicted by an extended Main Mechanical Forces approach and validated with molecular dynamics simulations

Article Title: Unraveling pH-dependent peptide conformational transitions via integration of main mechanical forces and side-chain interactions

Article References: Larocca, M., Floresta, G., Verderese, D., & Cilibrizzi, A. (2026). Unraveling pH-dependent peptide conformational transitions via integration of main mechanical forces and side-chain interactions. Frontiers in Chemical Biology, 5, Article 1914849. https://doi.org/10.3389/fchbi.2026.1914849

Image Credits: AI Generated

DOI: 10.3389/fchbi.2026.1914849

Keywords: peptide folding, pH-responsive peptides, Main Mechanical Forces, molecular dynamics, protonation states, non-covalent interactions, beta-hairpin, dihedral angles, pKa prediction, computational chemistry, conformational switches, drug delivery

The strategy addresses a central challenge in cancer immunotherapy. Many treatments can kill tumour cells, but cell death does not automatically produce effective antitumour immunity. For immune cells to recognize and attack cancer, dying tumour cells must release or display molecular signals that stimulate antigen-presenting cells. These signals, often described as damage-associated molecular patterns, can promote the uptake of tumour material by dendritic cells and help initiate T-cell responses. The researchers sought to design a form of cell death that would not simply eliminate tumour cells, but would also make their destruction immunologically productive.

The key component, aMP₍C16₎-CA₅₀, is a synthetic acid-responsive membranolytic peptide. Peptides of this class can disrupt lipid membranes by interacting with their surfaces and inserting into the bilayer, potentially forming defects or pores that compromise membrane integrity. What distinguishes this molecule is its hierarchical response to acidity. Tumour tissues commonly possess a mildly acidic extracellular environment, while lysosomes inside cells are substantially more acidic. The peptide was designed to respond to these changing pH conditions in stages, allowing its activity to be controlled by both location and time.

This sequence begins as the peptide encounters the acidic environment surrounding tumour cells and subsequently enters the cells. Once transported into lysosomes, where the pH is lower, the molecule becomes more strongly activated and damages lysosomal membranes. Lysosomal rupture releases enzymes and other contents into the cytoplasm, generating intense intracellular stress and activating inflammatory pathways. The plasma membrane then ruptures later, rather than simultaneously. According to the study, this delay is crucial: it gives the tumour cell time to develop an inflammatory transcriptional response before its final collapse and may improve the quality of the immune signals released during lysis.

The researchers describe this programmed process as immunogenic membranolytic cell death, or mLCD. Its defining feature is therefore not merely membrane destruction, but the spatiotemporal coordination of membrane damage. The order in which the lysosomal and plasma membranes fail can influence how a dying cell communicates with the immune system. Early lysosomal disruption may activate intracellular danger pathways, while delayed plasma-membrane rupture releases tumour-associated antigens and inflammatory mediators into the surrounding tissue. This combination could provide immune cells with both the warning signals and the tumour-specific material needed to mount a coordinated response.

Laboratory experiments indicated that aMP₍C16₎-CA₅₀ activated inflammatory gene-expression programs in tumour cells. These programs increased the ability of tumour-cell material to stimulate antigen presentation by dendritic cells. Antigen presentation is a critical bridge between innate and adaptive immunity: dendritic cells process proteins from damaged cells, load fragments onto major histocompatibility complex class I molecules and display them to T cells. When the displayed fragments originate from tumour cells, this interaction can help activate cytotoxic T lymphocytes capable of recognizing and killing cancer cells elsewhere in the body.

The findings also connect the peptide’s membrane-disrupting kinetics to the performance of immune checkpoint blockade. Checkpoint inhibitors, including therapies aimed at pathways such as PD-1, PD-L1 or CTLA-4, can restore T-cell activity, but they often work best when a tumour has already generated a strong immune response. By increasing antigen release and inflammatory signalling, the programmed mLCD approach may help convert immunologically quiet tumours into more responsive ones. In the reported experiments, aMP₍C16₎-CA₅₀ substantially enhanced the antitumour effects of immune checkpoint blockade, suggesting that the peptide could function as an immune-priming treatment rather than as a stand-alone cytotoxic agent.

The study further reports that systemic administration of the peptide was well tolerated in mice, an important consideration for any membrane-lytic therapy. Molecules that disrupt membranes can raise concerns about damage to healthy tissues, red blood cells or vital organs. The researchers’ pH-dependent design is intended to concentrate activity in acidic tumour environments and intracellular lysosomes, potentially limiting unwanted effects in normal tissues. However, the safety results remain preclinical. The distribution, metabolism, immune effects and toxicity of the peptide will need to be examined in more advanced animal studies before its relevance to human treatment can be determined.

The work illustrates a broader shift in cancer-drug design: instead of treating cell death as a single endpoint, researchers are attempting to program how, where and when a tumour cell dies. By manipulating membrane biology with a synthetic peptide, the team created a death process that links physical destruction to inflammatory gene activation and adaptive immune stimulation. If the concept can be translated safely beyond mice, pH-responsive membranolytic peptides could become a versatile platform for improving immunotherapy, particularly in tumours that currently resist checkpoint inhibitors. For now, the study provides a striking example of how precisely timed cellular damage can transform tumour-cell death into an active signal for the immune system.

Subject of Research:
A pH-responsive synthetic membranolytic peptide designed to induce immunogenic membranolytic cell death in tumour cells and enhance immune checkpoint blockade therapy.

Article Title:
Membranolytic peptide programs immunogenic cell death for cancer therapy

Article References:
Yuan, Y., Liang, L., Li, J. et al. “Membranolytic peptide programs immunogenic cell death for cancer therapy.” Nature (2026). https://doi.org/10.1038/s41586-026-10899-5

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41586-026-10899-5

Keywords:
Immunogenic cell death, membranolytic peptide, cancer immunotherapy, pH-responsive therapy, lysosomal membrane rupture, plasma membrane rupture, dendritic cells, T-cell activation, immune checkpoint blockade, tumour microenvironment